A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Medizinische Universitat Wien, Vienna

Salzburger Landkliniken St. Johanns-Spital, Salzburg

Universitaetsklinik Innsbruck, Innsbruck

Alexandra General Hospital of Athens, Athens

Karolinska University Hospital Huddinge, Stockholm

Lund University Hosptial, Lund

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario de Salamanca, Salamanca

Hospital Universitario Dr. Pesset, Valencia

Parkview Research Center, Fort Wayne

University of Kansas Hospital, Westwood

MD Anderson Cancer Center, Houston

Falu lasarett, Falun SE

OHSU, Portland

City of Hope Cancer Center, Duarte

Cancer Center of Central Connecticut, Southington

Indiana University Cancer Center, Indianapolis

University of Maryland School of Med, Baltimore

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Morristown Memorial Hosp, Morristown

UMCU Utrecht, Utrecht

Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona)

Helsingborg hospital, Helsingborg